Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Genmab

This page shows the latest Genmab news and features for those working in and with pharma, biotech and healthcare.

FDA clears first-line use for J&J’s myeloma drug Darzalex

FDA clears first-line use for J&J’s myeloma drug Darzalex

Duato. J&J licensed Darzalex from Danish biotech Genmab in 2012. Commenting on the latest approval, Genmab chief executive Jan van de Winkel said Darzalex has become the first antibody therapeutic

Latest news

More from news
Approximately 4 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    469. Genmab (DK). Gilead (US). Licence. DuoBody technology platform to develop bispecific antibody candidates for targeting HIV plus option to second licence.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Exclusive global licence. 510. Genmab. Novo Nordisk. Bispecific antibody candidates outside oncology indications.

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Four years ago Genmab started working with Seattle Genetics' ADC technology and has now signed a new deal using a Genmab antibody. The creative aspect of this deal is that Seattle ... has retained an option to increase the Genmab royalties to double

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    Genmab/ Janssen. Milestone payment. Daratumumab, anti-CD38 mAb for multiple myeloma (p2 milestone).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • EUSA Pharma appoints Rolf Hoffmann to its board EUSA Pharma appoints Rolf Hoffmann to its board

    Hoffman, who is currently chairman of Biotest and sits on the board of directors of Genmab, brings over 30 years’ pharmaceutical experience to his new position having served in a number

  • Dr Jan van de Winkel joins Austrian biotech Hookipa Dr Jan van de Winkel joins Austrian biotech Hookipa

    Current president and chief executive officer of Genmab, Dr van de Winkel joins the board with over 25 years’ experience in the therapeutic antibody field. ... Dr van de Winkel’s career experience has seen him serve Medarex Europe as its vice

  • Former Novartis exec joins Genmab Former Novartis exec joins Genmab

    Dr Judith Klimovsky becomes chief development officer. Copenhagen, Denmark-based Genmab has appointed Dr Judith Klimovsky as executive vice president and chief development officer. ... Jan van de Winkel, Genmab's chief executive, said: “We are very

  • bmore creative hires Kush Rach as new business director bmore creative hires Kush Rach as new business director

    at Charles River Laboratories, where he worked on clinical trial programmes for Ferring, Genmab, AstraZeneca, and Aerocrine (spending much of his time in Scandinavia).

  • Agneta Svedberg appointed COO at Zealand Pharma Agneta Svedberg appointed COO at Zealand Pharma

    Svedberg has more than 20 years of experience in the industry, most of which has been spent in northern Europe and includes a ten-year spell with Genmab in Denmark, where

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Quick links

Infographics

Multimedia